Crinetics Pharmaceuticals, Inc. (CRNX): Price and Financial Metrics
GET POWR RATINGS... FREE!
CRNX POWR Grades
- Value is the dimension where CRNX ranks best; there it ranks ahead of 33.64% of US stocks.
- The strongest trend for CRNX is in Stability, which has been heading down over the past 177 days.
- CRNX ranks lowest in Stability; there it ranks in the 12th percentile.
CRNX Stock Summary
- The ratio of debt to operating expenses for CRINETICS PHARMACEUTICALS INC is higher than it is for about just 5.42% of US stocks.
- CRNX's price/sales ratio is 176.28; that's higher than the P/S ratio of 98.09% of US stocks.
- Revenue growth over the past 12 months for CRINETICS PHARMACEUTICALS INC comes in at 339.43%, a number that bests 97.66% of the US stocks we're tracking.
- If you're looking for stocks that are quantitatively similar to CRINETICS PHARMACEUTICALS INC, a group of peers worth examining would be IMTX, INVZ, ACRS, CARA, and AFMD.
- Visit CRNX's SEC page to see the company's official filings. To visit the company's web site, go to www.crinetics.com.
CRNX Valuation Summary
- CRNX's price/sales ratio is 176.3; this is 3651.06% higher than that of the median Healthcare stock.
- CRNX's price/earnings ratio has moved up 28.8 over the prior 57 months.
Below are key valuation metrics over time for CRNX.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| CRNX | 2023-03-24 | 176.3 | 2.6 | -5.1 | -4.9 |
| CRNX | 2023-03-23 | 178.4 | 2.7 | -5.2 | -5.0 |
| CRNX | 2023-03-22 | 176.7 | 2.6 | -5.1 | -4.9 |
| CRNX | 2023-03-21 | 184.0 | 2.8 | -5.3 | -5.1 |
| CRNX | 2023-03-20 | 191.8 | 2.9 | -5.5 | -5.3 |
| CRNX | 2023-03-17 | 196.3 | 2.9 | -5.7 | -5.5 |
CRNX's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- CRNX has a Quality Grade of C, ranking ahead of 31.2% of graded US stocks.
- CRNX's asset turnover comes in at 0 -- ranking 441st of 682 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows CRNX's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.000 | NA | -1.476 |
| 2021-03-31 | 0.000 | NA | -1.211 |
| 2020-12-31 | 0.000 | 1 | -1.064 |
| 2020-09-30 | 0.002 | 1 | -0.952 |
| 2020-06-30 | 0.006 | 1 | -0.913 |
| 2020-03-31 | 0.007 | 1 | -0.741 |
CRNX Price Target
For more insight on analysts targets of CRNX, see our CRNX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $37.40 | Average Broker Recommendation | 1.4 (Strong Buy) |
CRNX Stock Price Chart Interactive Chart >
CRNX Price/Volume Stats
| Current price | $15.94 | 52-week high | $27.86 |
| Prev. close | $15.31 | 52-week low | $15.23 |
| Day low | $15.36 | Volume | 603,100 |
| Day high | $16.06 | Avg. volume | 424,953 |
| 50-day MA | $18.82 | Dividend yield | N/A |
| 200-day MA | $18.84 | Market Cap | 859.31M |
Crinetics Pharmaceuticals, Inc. (CRNX) Company Bio
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is CRN00808, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly. The company is also developing CRN02481, an oral selective nonpeptide somatostatin type 5 receptor agonist used for the treatment of congenital hyperinsulinism; and CRN01941, an oral, selective nonpeptide sst2 biased agonist designed for the treatment of neuroendocrine tumors. Crinetics Pharmaceuticals, Inc. was founded in 2008 and is based in San Diego, California.
Latest CRNX News From Around the Web
Below are the latest news stories about CRINETICS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate CRNX as an investment opportunity.
Top 10 Growth Stocks in BiotechIn this article, we will discuss the Top 10 Growth Stocks in Biotech. You can skip our industry overview and go directly to the Top 5 Growth Stocks in Biotech. The biotech industry encompasses a wide range of fields, including genetic engineering, biomanufacturing, bioinformatics, and synthetic biology. It has the potential to transform many aspects […] |
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)SAN DIEGO, March 10, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that on March 10, 2023, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 250,300 shares of its common stock to eight new non-exec |
We Think Crinetics Pharmaceuticals (NASDAQ:CRNX) Can Afford To Drive Business GrowthJust because a business does not make any money, does not mean that the stock will go down. For example, although... |
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q4 Loss, Lags Revenue EstimatesCrinetics Pharmaceuticals, Inc. (CRNX) delivered earnings and revenue surprises of -2.44% and 5.47%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock? |
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate UpdatePaltusotine’s Phase 3 PATHFNDR-1 study enrollment complete and topline data expected in 3Q 2023Paltusotine’s Phase 3 PATHFNDR-2 study enrollment ongoing with topline data now expected in 1Q 2024Pending a successful outcome from the PATHFNDR studies, an NDA submission in acromegaly is expected in 2024Paltusotine’s Phase 2 study in carcinoid syndrome on track for data in 2H 2023CRN04894’s studies in Cushing’s disease and congenital adrenal hyperplasia commenced in 1Q 2023 SAN DIEGO, Feb. 28, 2023 |
CRNX Price Returns
| 1-mo | -18.84% |
| 3-mo | -12.90% |
| 6-mo | -18.84% |
| 1-year | -16.11% |
| 3-year | 5.56% |
| 5-year | N/A |
| YTD | -12.90% |
| 2022 | -35.59% |
| 2021 | 101.35% |
| 2020 | -43.76% |
| 2019 | -16.34% |
| 2018 | N/A |
Continue Researching CRNX
Want to do more research on Crinetics Pharmaceuticals Inc's stock and its price? Try the links below:Crinetics Pharmaceuticals Inc (CRNX) Stock Price | Nasdaq
Crinetics Pharmaceuticals Inc (CRNX) Stock Quote, History and News - Yahoo Finance
Crinetics Pharmaceuticals Inc (CRNX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...